PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure

Lingxuan Mo; Jae Geun Song; Hankyu Lee; Mengjia Zhao; Hyeon Young Kim; Yoon Ji Lee; Hyuk Wan Ko; Hyo Kyung Han

doi:10.1016/j.nano.2017.12.003

PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure

Lingxuan Mo, Jae Geun Song, Hankyu Lee, Mengjia Zhao, Hyeon Young Kim, Yoon Ji Lee, Hyuk Wan Ko, Hyo Kyung Han

Department of Biochemistry

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

This study aimed to design an effective formulation for enhancing the tumor-targeted delivery of sorafenib. Three sorafenib-loaded liposomal formulations including uncoated liposome (SF-Lip), hyaluronic acid-coated liposome (HA-SF-Lip), and PEGylated hyaluronic acid-coated liposome (PEG-HA-SF-Lip) were developed with narrow size distribution and high encapsulation efficiency. The cellular uptake and cytotoxicity of HA-SF-Lip and PEG-HA-SF-Lip were greater than those of SF-Lip in MDA-MB-231 cells overexpressing CD44, whereas there were no significant differences in MCF-7 cells with low CD44 expression, indicating the CD44-mediated cellular uptake of coated liposomes. In comparison with sorafenib solution, PEG-HA-SF-Lip increased the systemic exposure and plasma half-life in rats by 3-fold and 2-fold, respectively. Consistently, PEG-HA-SF-Lip was the most effective for tumor growth inhibition through CD44 targeting in the MDA-MB-231 tumor xenograft mouse model. Taken together, the present study suggests that PEG-HA-SF-Lip might be effective for the tumor-targeted delivery of sorafenib with enhanced systemic exposure and longer blood circulation.

Original language	English
Pages (from-to)	557-567
Number of pages	11
Journal	Nanomedicine: Nanotechnology, Biology, and Medicine
Volume	14
Issue number	2
DOIs	https://doi.org/10.1016/j.nano.2017.12.003
Publication status	Published - 2018 Feb

Bibliographical note

Funding Information:
Funding: This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2016R1A2B2010097).

Publisher Copyright:
© 2017 Elsevier Inc.

All Science Journal Classification (ASJC) codes

Bioengineering
Medicine (miscellaneous)
Molecular Medicine
Biomedical Engineering
Materials Science(all)
Pharmaceutical Science

Access to Document

10.1016/j.nano.2017.12.003

Cite this

Mo, Lingxuan ; Song, Jae Geun ; Lee, Hankyu ; Zhao, Mengjia ; Kim, Hyeon Young ; Lee, Yoon Ji ; Ko, Hyuk Wan ; Han, Hyo Kyung. / PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2018 ; Vol. 14, No. 2. pp. 557-567.

@article{a28a4679bdef4b7db082b16aa7ae5ffd,

title = "PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure",

abstract = "This study aimed to design an effective formulation for enhancing the tumor-targeted delivery of sorafenib. Three sorafenib-loaded liposomal formulations including uncoated liposome (SF-Lip), hyaluronic acid-coated liposome (HA-SF-Lip), and PEGylated hyaluronic acid-coated liposome (PEG-HA-SF-Lip) were developed with narrow size distribution and high encapsulation efficiency. The cellular uptake and cytotoxicity of HA-SF-Lip and PEG-HA-SF-Lip were greater than those of SF-Lip in MDA-MB-231 cells overexpressing CD44, whereas there were no significant differences in MCF-7 cells with low CD44 expression, indicating the CD44-mediated cellular uptake of coated liposomes. In comparison with sorafenib solution, PEG-HA-SF-Lip increased the systemic exposure and plasma half-life in rats by 3-fold and 2-fold, respectively. Consistently, PEG-HA-SF-Lip was the most effective for tumor growth inhibition through CD44 targeting in the MDA-MB-231 tumor xenograft mouse model. Taken together, the present study suggests that PEG-HA-SF-Lip might be effective for the tumor-targeted delivery of sorafenib with enhanced systemic exposure and longer blood circulation.",

author = "Lingxuan Mo and Song, {Jae Geun} and Hankyu Lee and Mengjia Zhao and Kim, {Hyeon Young} and Lee, {Yoon Ji} and Ko, {Hyuk Wan} and Han, {Hyo Kyung}",

note = "Funding Information: Funding: This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2016R1A2B2010097). Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2018",

month = feb,

doi = "10.1016/j.nano.2017.12.003",

language = "English",

volume = "14",

pages = "557--567",

journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",

issn = "1549-9634",

publisher = "Elsevier Inc.",

number = "2",

}

PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure. / Mo, Lingxuan; Song, Jae Geun; Lee, Hankyu; Zhao, Mengjia; Kim, Hyeon Young; Lee, Yoon Ji; Ko, Hyuk Wan; Han, Hyo Kyung.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 14, No. 2, 02.2018, p. 557-567.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure

AU - Mo, Lingxuan

AU - Song, Jae Geun

AU - Lee, Hankyu

AU - Zhao, Mengjia

AU - Kim, Hyeon Young

AU - Lee, Yoon Ji

AU - Ko, Hyuk Wan

AU - Han, Hyo Kyung

N1 - Funding Information: Funding: This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2016R1A2B2010097). Publisher Copyright: © 2017 Elsevier Inc.

PY - 2018/2

Y1 - 2018/2

N2 - This study aimed to design an effective formulation for enhancing the tumor-targeted delivery of sorafenib. Three sorafenib-loaded liposomal formulations including uncoated liposome (SF-Lip), hyaluronic acid-coated liposome (HA-SF-Lip), and PEGylated hyaluronic acid-coated liposome (PEG-HA-SF-Lip) were developed with narrow size distribution and high encapsulation efficiency. The cellular uptake and cytotoxicity of HA-SF-Lip and PEG-HA-SF-Lip were greater than those of SF-Lip in MDA-MB-231 cells overexpressing CD44, whereas there were no significant differences in MCF-7 cells with low CD44 expression, indicating the CD44-mediated cellular uptake of coated liposomes. In comparison with sorafenib solution, PEG-HA-SF-Lip increased the systemic exposure and plasma half-life in rats by 3-fold and 2-fold, respectively. Consistently, PEG-HA-SF-Lip was the most effective for tumor growth inhibition through CD44 targeting in the MDA-MB-231 tumor xenograft mouse model. Taken together, the present study suggests that PEG-HA-SF-Lip might be effective for the tumor-targeted delivery of sorafenib with enhanced systemic exposure and longer blood circulation.

AB - This study aimed to design an effective formulation for enhancing the tumor-targeted delivery of sorafenib. Three sorafenib-loaded liposomal formulations including uncoated liposome (SF-Lip), hyaluronic acid-coated liposome (HA-SF-Lip), and PEGylated hyaluronic acid-coated liposome (PEG-HA-SF-Lip) were developed with narrow size distribution and high encapsulation efficiency. The cellular uptake and cytotoxicity of HA-SF-Lip and PEG-HA-SF-Lip were greater than those of SF-Lip in MDA-MB-231 cells overexpressing CD44, whereas there were no significant differences in MCF-7 cells with low CD44 expression, indicating the CD44-mediated cellular uptake of coated liposomes. In comparison with sorafenib solution, PEG-HA-SF-Lip increased the systemic exposure and plasma half-life in rats by 3-fold and 2-fold, respectively. Consistently, PEG-HA-SF-Lip was the most effective for tumor growth inhibition through CD44 targeting in the MDA-MB-231 tumor xenograft mouse model. Taken together, the present study suggests that PEG-HA-SF-Lip might be effective for the tumor-targeted delivery of sorafenib with enhanced systemic exposure and longer blood circulation.

UR - http://www.scopus.com/inward/record.url?scp=85042760475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042760475&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2017.12.003

DO - 10.1016/j.nano.2017.12.003

M3 - Article

C2 - 29248675

AN - SCOPUS:85042760475

VL - 14

SP - 557

EP - 567

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 2

ER -

PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this